Pascal Deschatelets - 10 Jul 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Signature
/s/ David Watson, attorney-in-fact for Pascal Deschatelets
Issuer symbol
APLS
Transactions as of
10 Jul 2023
Net transactions value
-$965,205
Form type
4
Filing time
11 Jul 2023, 17:37:06 UTC
Previous filing
09 Jun 2023
Next filing
09 Aug 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $49,395 +18,500 +1.8% $2.67* 1,058,813 10 Jul 2023 Direct F1
transaction APLS Common Stock Sale $1,014,600 -12,000 -1.1% $84.55 1,046,813 10 Jul 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -18,500 -20% $0.000000 72,994 10 Jul 2023 Common Stock 18,500 $2.67 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This is a scheduled exercise and sale from a 10B5-1 trading plan.
F2 This stock option was granted on 12/5/2013 and is fully vested.